The Advantage of Developing Biobetter Versions of Existing Drugs
We believe that the CTP technology will be broadly applicable to many of the best-selling therapeutic proteins in the market and will be attractive to potential partners because it will allow them to extend proprietary rights for therapeutic proteins with near-term patent expirations.
Our strategy of targeting therapeutic proteins already approved by the FDA, with proven safety and efficacy, allows us to lower the risk profile of our proprietary development portfolio compared to de novo therapeutic protein development. This will increase the ease of therapeutic protein development because modifying an existing therapeutic protein is significantly easier and less risky than developing a new one. This strategy should also lead to less expensive, faster clinical trials since endpoints and study protocols will be the same as those used for existing therapies.